JP2025507472A5 - - Google Patents

Info

Publication number
JP2025507472A5
JP2025507472A5 JP2023580943A JP2023580943A JP2025507472A5 JP 2025507472 A5 JP2025507472 A5 JP 2025507472A5 JP 2023580943 A JP2023580943 A JP 2023580943A JP 2023580943 A JP2023580943 A JP 2023580943A JP 2025507472 A5 JP2025507472 A5 JP 2025507472A5
Authority
JP
Japan
Prior art keywords
hcov
cov
pharmaceutically acceptable
sars
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507472A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/076078 external-priority patent/WO2023165334A1/zh
Publication of JP2025507472A publication Critical patent/JP2025507472A/ja
Publication of JP2025507472A5 publication Critical patent/JP2025507472A5/ja
Pending legal-status Critical Current

Links

JP2023580943A 2022-03-01 2023-02-15 ケトアミド系誘導体及びその製薬における使用 Pending JP2025507472A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210199543 2022-03-01
CN202210199543.5 2022-03-01
PCT/CN2023/076078 WO2023165334A1 (zh) 2022-03-01 2023-02-15 酮酰胺类衍生物及其制药用途

Publications (2)

Publication Number Publication Date
JP2025507472A JP2025507472A (ja) 2025-03-21
JP2025507472A5 true JP2025507472A5 (cg-RX-API-DMAC7.html) 2025-12-17

Family

ID=87830006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580943A Pending JP2025507472A (ja) 2022-03-01 2023-02-15 ケトアミド系誘導体及びその製薬における使用

Country Status (5)

Country Link
US (1) US20250064789A1 (cg-RX-API-DMAC7.html)
EP (1) EP4488264A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025507472A (cg-RX-API-DMAC7.html)
CN (1) CN116693447B (cg-RX-API-DMAC7.html)
WO (1) WO2023165334A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US20250064789A1 (en) * 2022-03-01 2025-02-27 Westvac Biopharma Co., Ltd. Ketoamide derivatives and pharmaceutical uses thereof
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4544993A (en) * 1992-06-24 1994-01-24 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
JPH08208462A (ja) * 1994-11-24 1996-08-13 Takeda Chem Ind Ltd カテプシンl阻害剤
WO1998018485A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. The use of calpain inhibitors to treat ocular neural pathology
HRP20000788A2 (en) * 1998-04-20 2001-06-30 Basf Ag Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
EP1553964A4 (en) * 2002-09-25 2009-08-12 Georgia Tech Res Inst KETOAMID INHIBITORS IN CHRONIC NERVE DISEASES
US8236798B2 (en) * 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US8598211B2 (en) * 2009-12-22 2013-12-03 Abbvie Inc. Carboxamide compounds and their use as calpain inhibitors IV
GB201001070D0 (en) * 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
KR20150065885A (ko) * 2012-10-11 2015-06-15 에프. 호프만-라 로슈 아게 케토아마이드 이뮤노프로테아좀 억제제
US10934261B2 (en) * 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
IL297069A (en) * 2020-04-10 2022-12-01 Cocrystal Pharma Inc Replication inhibitors of norovirus and corona virus
BR112022025037A2 (pt) * 2020-06-10 2023-02-14 Aligos Therapeutics Inc Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus
CN115960088B (zh) * 2020-07-31 2024-07-26 四川大学 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
CN114057702B (zh) * 2020-07-31 2022-09-30 四川大学 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
WO2022119756A1 (en) * 2020-12-04 2022-06-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection
WO2022265577A2 (en) * 2021-06-15 2022-12-22 Agency For Science, Technology And Research Coronavirus enzyme modulators, methods of synthesis and uses thereof
JP2023000996A (ja) * 2021-06-18 2023-01-04 ラクオリア創薬株式会社 プロテアーゼ阻害剤としてのケトアミド誘導体
US20250064789A1 (en) * 2022-03-01 2025-02-27 Westvac Biopharma Co., Ltd. Ketoamide derivatives and pharmaceutical uses thereof

Similar Documents

Publication Publication Date Title
JP2023017050A5 (cg-RX-API-DMAC7.html)
PE20242299A1 (es) Composiciones agonistas de gip/glp1
IL311376B2 (en) Azetidine and pyrrolidine parp1 inhibitors and uses thereof
JP2007533686A5 (cg-RX-API-DMAC7.html)
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
BRPI0413186A (pt) composição de fexofenadina e processo para preparação da mesma
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
PE20250018A1 (es) Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-73-fluoro-35- metoxi-32 ,5-dioxo-14-(trifluorometil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola- 2(1,2),7(1)-dibencenaheptafano-74-carboxamida
NO20082181L (no) Formuleringer av Fispemifen
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
MXPA05005781A (es) Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
MX2021003670A (es) Derivados biciclicos como moduladores del receptor gabaa a5.
SE0401655D0 (sv) New compounds
CO2026000726A2 (es) Una forma farmacéutica sólida de dosificación bucodispersable de safinamida
UA89684C2 (ru) Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
JP2002534477A5 (cg-RX-API-DMAC7.html)
AR127966A1 (es) Formulaciones tópicas de inhibidores de pi3k-delta
AR124542A1 (es) Métodos de tratamiento
UY29445A1 (es) Composiciones para la transmisión transmucosa oral de la metformina